Health Market Science

Accuracy and completeness are the ultimate objectives of transparency reporting and the primary dimensions by which data quality is measured in the aggregate spend arena. With unlimited resources and unlimited time, this objective could easily be attained by most organizations; but in the transparency reporting game, the limiting factor is time.  

Just when you thought it might all be a bad dream, the Physician Payments Sunshine Provisions proposed rule emerges.

While no one is surprised that HHS missed its October 1, 2011 deadline for publishing reporting guidelines to the healthcare industry for Physician Payments Sunshine Act reporting, the bottom line is a lack of performance on CMS’s part to provide direction to the industry should not be (and likely will not be) considered an excuse for a lack of preparedness for data collection by covered reporting entities (U.S. drug, medical device, biological or medical supply manufacturers).

After a well-attended session at CBI's 5th Annual Tracking State Laws and Aggregate Spend , Health Market Science and CBI decided to create a follow-up webinar that echoes some points offered in  my August presentation, while offering more detail on the cost of poor quality data.

As a speaker at the CBI Aggregate Spend Conference last week, (with a timely agenda and a great turnout) I was looking forward to gauging Life Science organizations’ response to what will soon be the final regs of the Sunshine Act. I was quickly enlightened.  With the first session, I could tell participants were still learning the options for overcoming the challenges of transparency. In fact, some are still in the planning stage!